ClinicalTrials.gg
CompletedNCT00670449Updated Sep 4, 2013Results posted

An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis

A Phase 2 interventional study of Fingolimod in Multiple Sclerosis, sponsored by Novartis. Completed at 20 sites in Japan. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-09-04.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.

Enrollment
20th of 34
143 · median 167
Started
2008
with 2 others
Phase 2
4 of 34
none open now
Registered
7th of 34
by date
Lead sponsor
10 of 34
Novartis

Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 20th largest by enrollment, is one of 3 that started in 2008, is one of 4 in phase 2, and was the 7th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing fingolimod in Multiple Sclerosis, or all of them as a file.
02

Study summary

This study was an extension study of NCT00537082. This study was designed to evaluate the efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720) to relapsing multiple sclerosis.

Read the detailed description

A decision was made to switch all patients on fingolimod 1.25 mg/day to fingolimod 0.5 mg/day in an amendment to the study protocol. The study became open-label with all patients receiving fingolimod 0.5 mg/day on 22 Feb 2010.

The efficacy data for Months 0-6 in this study report is from the core study NCT00537082.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • FTY720
  • multiple sclerosis
  • MS
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who completed 6 months of treatment with the study drug and the Month 6 visit in the core study NCT00537082.
  • Females of who have a negative pregnancy test in the core study NCT00537082.

Exclusion criteria

Exclusion Criteria:

  • Patients who permanently discontinued study drug treatment prior to the Month 6 visit in the core study NCT00537082.

Other protocol-defined inclusion/exclusion criteria applied to the study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    Fingolimod 0.5 mg

    Patients who received fingolimod 0.5 orally once daily in the core study continued on the same dose in this extension study.

    Drug: Fingolimod

  • Experimental
    Fingolimod 1.25 mg

    Patients who received fingolimod 1.25 mg orally once daily in the core study continued on the same dose in this extension study.

    Drug: Fingolimod

  • Experimental
    Placebo-fingolimod

    Patients who were randomized to placebo in the core study were re-randomized to either fingolimod 0.5 or 1.25 mg (1:1) orally once daily in this extension study.

    Drug: Fingolimod

Interventions

  • Fingolimod was supplied in capsules.

    Also known as: Gilenya, Imsera

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Free of Gd-enhanced T1 Weighted Magnetic Resonance Imaging (MRI) Lesions

    To ensure consistency, MRI scans were evaluated centrally at the Institute of Neurotherapeutics in Kyoto, Japan. After checking the scans for completeness and quality, all scans were analyzed by blinded readers (experienced neurologists). The number of Gd-enhanced T1 weighted MRI lesions were counted and recorded. Lesions expanding through several slices were counted as only 1 lesion.

    Time frame: Months 6, 9, 12, 18, 24, 36, and 48

Secondary outcomes

  1. Percentage of Patients Free of New or Newly Enlarged T2 Weighted MRI Lesions

    To ensure consistency, MRI scans were evaluated centrally at the Institute of Neurotherapeutics in Kyoto, Japan. After checking the scans for completeness and quality, all scans were analyzed by blinded readers (experienced neurologists). The number of new or newly enlarged T2 weighted MRI lesions were counted and recorded. New lesions were identified by comparing each lesion with previous scans. Lesions expanding through several slices were counted as only 1 lesion.

    Time frame: Months 0-3, 3-6, 6-9, 9-12, 12-18, 18-24, 24-36,36-48, and 48 to the end of the study (up to 4 years)

  2. Aggregate Annualized Relapse Rate (ARR) Based on Confirmed Relapses

    The ARR was defined as the total number of relapses for all patients in the treatment arm / total number of days in the study for all patients in the treatment arm for the specific period of time × 365.25. General definition of relapse: Appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from the onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\< 37.5°C) or infection. A relapse was to be confirmed by a neurologist trained on the Expanded Disability Status Scale (EDSS). A relapse must be accompanied by an increase of at least half a step (0.5) on the EDSS or an increase of 1 point on 2 different Functional Systems (FS) of the EDSS or 2 points on 1 of the FS (excluding Bowel/Bladder or Cerebral FS).

    Time frame: Months 0-6, 6-12, 12-24, 24-36, 36-48, and 48 to the end of the study (up to 4 years)

  3. Percentage of Patients Relapse-free at the End of the Study

    Patients who did not experience any relapses confirmed by a neurologist during the study were regarded as relapse-free patients.

    Time frame: Baseline to the end of the study (up to 4 years)

  4. Percentage of Patients Free From 3-month and 6-month Confirmed Disability Progression at Their Last Expanded Disability Status Scale (EDSS) Assessment

    Disability progression was measured by the EDSS score. A trained neurologist grades the multiple sclerosis (MS) disability of the patient on a scale of 0-5 (no to severe disability) in 8 Functional Systems (FS): Pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral (or mental), and other. The EDSS score ranges from 0-10 (normal to dead) with higher scores indicating greater disability. A 3-month confirmed disability progression was defined as a 3-month sustained increase from baseline in the EDSS score, that is, every EDSS score obtained (scheduled or unscheduled) within 3-months after the first progression met the following progression criteria: One point (1) increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point (0.5) increase in patients with baseline EDSS score of 5.5 or above. A 6-month confirmed disability progression was defined exactly the same except that the sustained progression had to last 6 months.

    Time frame: Baseline to the end of the study (up to 4 years)

  5. Change From Core Study Baseline in the Expanded Disability Status Scale (EDSS) Score

    Disability progression was measured by the EDSS score. A trained neurologist grades the multiple sclerosis (MS) disability of the patient on a scale of 0-5 (no to severe disability) in 8 Functional Systems (FS): Pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral (or mental), and other. The EDSS score ranges from 0-10 (normal to dead) with higher scores indicating greater disability. A 3-month confirmed disability progression was defined as a 3-month sustained increase from baseline in the EDSS score, that is, every EDSS score obtained (scheduled or unscheduled) within 3-months after the first progression met the following progression criteria: One point (1) increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point (0.5) increase in patients with baseline EDSS score of 5.5 or above. A 6-month confirmed disability progression was defined exactly the same except that the sustained progression had to last 6 months.

    Time frame: Baseline to Months 12, 24, 36, 48, and end of study (up to 4 years)

07

Results

Posted Sep 4, 2013

Participant flow

Participant flow — Overall Study
MilestoneFingolimod 0.5 mgFingolimod 1.25 mgPlacebo-fingolimod 0.5 mgPlacebo-fingolimod 1.25 mg
Started47462723
Switched to 0.5mg (open label)45412317
Completed38361815
Not completed91098
Withdrew: Adverse event6285
Withdrew: Protocol deviation1201
Withdrew: Administrative problems0201
Withdrew: Subject withdrew consent0201
Withdrew: Unsatisfactory therapeutic effect2010
Withdrew: Abnormal laboratory value(s)0200

Outcome measures

PrimaryPercentage of Patients Free of Gd-enhanced T1 Weighted Magnetic Resonance Imaging (MRI) Lesions

To ensure consistency, MRI scans were evaluated centrally at the Institute of Neurotherapeutics in Kyoto, Japan. After checking the scans for completeness and quality, all scans were analyzed by blinded readers (experienced neurologists). The number of Gd-enhanced T1 weighted MRI lesions were counted and recorded. Lesions expanding through several slices were counted as only 1 lesion.

Time frame:
Months 6, 9, 12, 18, 24, 36, and 48
Reported as:
Number · Percentage of patients
Percentage of Patients Free of Gd-enhanced T1 Weighted Magnetic Resonance Imaging (MRI) Lesions
Percentage of patientsFingolimod 0.5 mgFingolimod 1.25 mgPlacebo-fingolimod
Month 6 (N=44, 48, 50)88.697.958.0
Month 9 (N=44, 39, 41)90.994.992.7
Month 12 (N=44, 42, 36)97.797.688.9
Month 18 (N=42, 40, 37)92.992.594.6
Month 24 (N=38, 39, 33)94.794.990.9
Month 36 (N=25, 21, 22)92.085.790.9
Month 48 (N=3, 4, 1)100.075.0100.0
SecondaryPercentage of Patients Free of New or Newly Enlarged T2 Weighted MRI Lesions

To ensure consistency, MRI scans were evaluated centrally at the Institute of Neurotherapeutics in Kyoto, Japan. After checking the scans for completeness and quality, all scans were analyzed by blinded readers (experienced neurologists). The number of new or newly enlarged T2 weighted MRI lesions were counted and recorded. New lesions were identified by comparing each lesion with previous scans. Lesions expanding through several slices were counted as only 1 lesion.

Time frame:
Months 0-3, 3-6, 6-9, 9-12, 12-18, 18-24, 24-36,36-48, and 48 to the end of the study (up to 4 years)
Reported as:
Number · Percentage of patients
Percentage of Patients Free of New or Newly Enlarged T2 Weighted MRI Lesions
Percentage of patientsFingolimod 0.5 mgFingolimod 1.25 mgPlacebo-fingolimod
Month 0 to 3 (N=49, 50, 51)69.460.045.1
Month 3 to 6 (N=43, 47, 48)86.091.543.8
Month 6 to 9 (N=44, 39, 40)88.692.370.0
Month 9 to 12 (N=44, 42, 35)93.295.285.7
Month 12 to 18 (N=43, 40, 37)88.490.091.9
Month 18 to 24 (N=39, 39, 33)94.992.387.9
Month 24 to 36 (N=25, 21, 22)92.090.590.9
Month 36 to 48 (N=3, 4, 1)100.0100.0100.0
Month 48 to end of study (N=3, 3, 1)100.0100.0100.0
SecondaryAggregate Annualized Relapse Rate (ARR) Based on Confirmed Relapses

The ARR was defined as the total number of relapses for all patients in the treatment arm / total number of days in the study for all patients in the treatment arm for the specific period of time × 365.25. General definition of relapse: Appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from the onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\< 37.5°C) or infection. A relapse was to be confirmed by a neurologist trained on the Expanded Disability Status Scale (EDSS). A relapse must be accompanied by an increase of at least half a step (0.5) on the EDSS or an increase of 1 point on 2 different Functional Systems (FS) of the EDSS or 2 points on 1 of the FS (excluding Bowel/Bladder or Cerebral FS).

Time frame:
Months 0-6, 6-12, 12-24, 24-36, 36-48, and 48 to the end of the study (up to 4 years)
Reported as:
Number · Relapses per year
Aggregate Annualized Relapse Rate (ARR) Based on Confirmed Relapses
Relapses per yearFingolimod 0.5 mgFingolimod 1.25 mgPlacebo-fingolimod
Month 0 to 6 (N=57, 54, 57)0.5390.4041.131
Month 6 to 12 (N=47, 46, 50)0.2270.2840.232
Month 12 to 24 (N=44, 43, 39)0.1660.2230.222
Month 24 to 36 (N=41, 40, 34)0.1910.0580.162
Month 36 to 48 (N=28, 23, 23)0.1640.0750.309
Month 48 to end of study (N=8, 6, 3)0.0000.0000.000
SecondaryPercentage of Patients Relapse-free at the End of the Study

Patients who did not experience any relapses confirmed by a neurologist during the study were regarded as relapse-free patients.

Time frame:
Baseline to the end of the study (up to 4 years)
Reported as:
Number · Percentage of patients
Percentage of Patients Relapse-free at the End of the Study
Percentage of patientsFingolimod 0.5 mgFingolimod 1.25 mgPlacebo-fingolimod
Percentage of Patients Relapse-free at the End of the Study45.2 (26.87 to 61.95)62.1 (46.63 to 74.26)48.3 (33.29 to 61.77)
SecondaryPercentage of Patients Free From 3-month and 6-month Confirmed Disability Progression at Their Last Expanded Disability Status Scale (EDSS) Assessment

Disability progression was measured by the EDSS score. A trained neurologist grades the multiple sclerosis (MS) disability of the patient on a scale of 0-5 (no to severe disability) in 8 Functional Systems (FS): Pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral (or mental), and other. The EDSS score ranges from 0-10 (normal to dead) with higher scores indicating greater disability. A 3-month confirmed disability progression was defined as a 3-month sustained increase from baseline in the EDSS score, that is, every EDSS score obtained (scheduled or unscheduled) within 3-months after the first progression met the following progression criteria: One point (1) increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point (0.5) increase in patients with baseline EDSS score of 5.5 or above. A 6-month confirmed disability progression was defined exactly the same except that the sustained progression had to last 6 months.

Time frame:
Baseline to the end of the study (up to 4 years)
Reported as:
Number · Percentage of patients
Percentage of Patients Free From 3-month and 6-month Confirmed Disability Progression at Their Last Expanded Disability Status Scale (EDSS) Assessment
Percentage of patientsFingolimod 0.5 mgFingolimod 1.25 mgPlacebo-fingolimod
Free from 3-month confirmed disability progression74.3 (55.04 to 86.31)82.4 (67.73 to 90.87)90.6 (78.63 to 95.99)
Free from 6-month confirmed disability progression87.1 (73.40 to 94.03)90.7 (76.94 to 96.44)92.3 (80.51 to 97.06)
SecondaryChange From Core Study Baseline in the Expanded Disability Status Scale (EDSS) Score

Disability progression was measured by the EDSS score. A trained neurologist grades the multiple sclerosis (MS) disability of the patient on a scale of 0-5 (no to severe disability) in 8 Functional Systems (FS): Pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral (or mental), and other. The EDSS score ranges from 0-10 (normal to dead) with higher scores indicating greater disability. A 3-month confirmed disability progression was defined as a 3-month sustained increase from baseline in the EDSS score, that is, every EDSS score obtained (scheduled or unscheduled) within 3-months after the first progression met the following progression criteria: One point (1) increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point (0.5) increase in patients with baseline EDSS score of 5.5 or above. A 6-month confirmed disability progression was defined exactly the same except that the sustained progression had to last 6 months.

Time frame:
Baseline to Months 12, 24, 36, 48, and end of study (up to 4 years)
Reported as:
Mean · Units on a scale
Change From Core Study Baseline in the Expanded Disability Status Scale (EDSS) Score
Units on a scaleFingolimod 0.5 mgFingolimod 1.25 mgPlacebo-fingolimod
Month 12 (N=45, 43, 40)-0.02 ± 0.464-0.02 ± 0.831-0.23 ± 0.800
Month 24 (N=42, 40, 35)-0.12 ± 0.723-0.06 ± 1.033-0.21 ± 0.789
Month 36 (N=25, 21, 23)0.16 ± 1.441-0.07 ± 0.912-0.37 ± 0.678
Month 48 (N=3, 4, 1)1.17 ± 0.764-0.63 ± 0.9460.00 ± 0.000
End of study (N=37, 36, 32)0.00 ± 1.225-0.17 ± 0.902-0.31 ± 0.830

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod 1.25 mg—5/46 (10.9%)43/46 (93.5%)
Fingolimod 0.5 mg—8/47 (17%)42/47 (89.4%)
Placebo-fingolimod 1.25 mg—5/23 (21.7%)21/23 (91.3%)
Placebo-fingolimod 0.5 mg—1/27 (3.7%)25/27 (92.6%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventFingolimod 1.25 mgFingolimod 0.5 mgPlacebo-fingolimod 1.25 mgPlacebo-fingolimod 0.5 mg
BradycardiaCardiac disorders0/460/472/230/27
LeukoencephalopathyNervous system disorders0/460/471/230/27
RadiculitisNervous system disorders0/460/471/230/27
Abortion inducedSurgical and medical procedures1/460/471/230/27
Neuromyelitis opticaNervous system disorders0/460/470/231/27
CataractEye disorders1/460/470/230/27
Tooth impactedGastrointestinal disorders1/460/470/230/27
AppendicitisInfections and infestations1/460/470/230/27
Urinary tract infectionInfections and infestations1/460/470/230/27
Eyeball ruptureInjury, poisoning and procedural complications1/460/470/230/27
Most frequent other events
Showing 10 of 52
Most frequent other events
EventFingolimod 1.25 mgFingolimod 0.5 mgPlacebo-fingolimod 1.25 mgPlacebo-fingolimod 0.5 mg
NasopharyngitisInfections and infestations28/4629/4712/2315/27
Liver function test abnormalInvestigations8/466/479/237/27
LymphopeniaBlood and lymphatic system disorders8/466/473/232/27
RashSkin and subcutaneous tissue disorders0/461/474/233/27
HeadacheNervous system disorders3/468/473/231/27
CystitisInfections and infestations7/463/471/232/27
LeukopeniaBlood and lymphatic system disorders5/462/471/234/27
StomatitisGastrointestinal disorders6/464/471/234/27
Atrioventricular block second degreeCardiac disorders0/460/473/230/27
DiarrhoeaGastrointestinal disorders6/463/472/231/27

Baseline characteristics

Age Continuous
Age Continuous(years)Fingolimod 0.5 mgFingolimod 1.25 mgPlacebo-fingolimod 0.5 mgPlacebo-fingolimod 1.25 mgTotal
Mean34.9 ± 8.9535.7 ± 8.8134.2 ± 9.0835.5 ± 8.4435.1 ± 8.78
Sex: Female, Male
Sex: Female, Male(Participants)Fingolimod 0.5 mgFingolimod 1.25 mgPlacebo-fingolimod 0.5 mgPlacebo-fingolimod 1.25 mgTotal
Female3331191497
Male14158946
08

Study locations

20 sites
  • Novartis Investigative Site
    Chiba, 276-8524, Japan
  • Novartis Investigative Site
    Ehime, 791-0295, Japan
  • Novartis Investigative Site
    Fukuoka, 807-8555, Japan
  • Novartis Investigative Site
    Gunma, 371-8511, Japan
  • Novartis Investigative Site
    Hyogo, 650-0017, Japan
  • Novartis Investigative Site
    Ibaraki, 305-8576, Japan
  • Novartis Investigative Site
    Kanagawa, 259-1193, Japan
  • Novartis Investigative Site
    Kyoto, 604-8453, Japan
  • Novartis Investigative Site
    Kyoto, 616-8255, Japan
  • Novartis Investigative Site
    Morioka, 020-8505, Japan
  • Novartis Investigative Site
    Niigata, 951-8520, Japan
  • Novartis Investigative Site
    Osaka, 556-0016, Japan
  • Novartis Investigative Site
    Osaka, 589-8511, Japan
  • Novartis Investigative Site
    Osaka, Japan
  • Novartis Investigative Site
    Sapporo, 060-8648, Japan
  • Novartis Investigative Site
    Tochigi, 329-0498, Japan
  • Novartis Investigative Site
    Tokyo, 113-8519, Japan
  • Novartis Investigative Site
    Tokyo, 145-0065, Japan
  • Novartis Investigative Site
    Tokyo, 162-8666, Japan
  • Novartis Investigative Site
    Wakayama, 641-8510, Japan
09

References and documents

Publications

  • Saida T, Itoyama Y, Kikuchi S, Hao Q, Kurosawa T, Ueda K, Auberson LZ, Tsumiyama I, Nagato K, Kira JI. Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study. BMC Neurol. 2017 Jan 28;17(1):17. doi: 10.1186/s12883-017-0794-5. PubMed 28129749 ↗
  • Kira J, Itoyama Y, Kikuchi S, Hao Q, Kurosawa T, Nagato K, Tsumiyama I, von Rosenstiel P, Zhang-Auberson L, Saida T. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurol. 2014 Jan 29;14:21. doi: 10.1186/1471-2377-14-21. PubMed 24475777 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2008
First posted
May 1, 2008
Start
Apr 2008
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
Sep 4, 2013
Last update
Sep 4, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00670449
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
May 1, 2008
Start date
Apr 2008
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Sep 4, 2013
Last update
Sep 4, 2013

Study contacts

Novartis Pharmaceuticals, Japan
principal investigator · 81-3-3797-8748
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion